U.S. markets closed
  • S&P Futures

    3,843.25
    +34.00 (+0.89%)
     
  • Dow Futures

    31,143.00
    +231.00 (+0.75%)
     
  • Nasdaq Futures

    13,061.25
    +150.25 (+1.16%)
     
  • Russell 2000 Futures

    2,234.60
    +35.40 (+1.61%)
     
  • Crude Oil

    62.65
    +1.15 (+1.87%)
     
  • Gold

    1,744.40
    +15.60 (+0.90%)
     
  • Silver

    26.95
    +0.51 (+1.95%)
     
  • EUR/USD

    1.2092
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.4600
    -0.0580 (-3.82%)
     
  • Vix

    27.95
    -0.94 (-3.25%)
     
  • GBP/USD

    1.3990
    +0.0067 (+0.48%)
     
  • USD/JPY

    106.6780
    +0.1760 (+0.17%)
     
  • BTC-USD

    46,766.03
    +228.77 (+0.49%)
     
  • CMC Crypto 200

    935.15
    +2.01 (+0.22%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    29,633.28
    +667.27 (+2.30%)
     

Adamas to Present at Upcoming Healthcare Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, is scheduled to present at the following investor conferences:

  • 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24 at 1:40 p.m. ET (10:40 a.m. PT)

  • Cowen 41st Annual Healthcare Conference on Tuesday, March 2 at 2:50 p.m. ET (11:50 a.m. PT)

  • H.C. Wainwright Global Life Sciences Conference. Prerecorded presentation available starting on Tuesday, March 9 at 7:30 a.m. ET (4:30 a.m. PT)

The webcasts will be accessible on the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations and will be available for 30 days.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Source: Adamas Pharmaceuticals, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005975/en/

Contacts

Media:
Sarah Mathieson
Vice President, Corporate Communications
510-450-3528
smathieson@adamaspharma.com

Investors:
Peter Vozzo
Managing Director
Westwicke/ICR
443-213-0505
peter.vozzo@westwicke.com